Orexo AB · OMXSTO:ORX
Orexo AB — Shareholder Meeting (April 2017)
15 slides from Orexo AB's shareholder meeting presentation, Apr 6, 2017
Slide 1: First profitable year in the history of Orexo AB
First profitable year in the history of Orexo AB Annual General Meeting April 6 2017 Nasdaq Stockholm: ORX US OTC Market: ORXOY (ADR)
Slide 2: Legal Disclaimer
Legal Disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orex
Slide 3: Orexo has completed a transformation of the company the last five years
Orexo has completed a transformation of the company the last five years • Restructure Abstral® agreement Sales growth leading to positive EBIT in 2016 • File Zubsolv® in the US (MSEK) 2012 800 • Establish Orexo US Inc subsidiary 700 • Launch Zubsolv in the US with CSO 600 2013 partner 500 • Internal
Slide 4: Apart from full-year profitability in 2016 several important milestones were reached
Apart from full-year profitability in 2016 several important milestones were reached Development Supply Commercial OX-CLI acquired by AZ for Prepared for future supply First large exclusive 5 MUSD chain enabling a agreement in FFS Medicaid Submitted Zubsolv® file to substantial reduction in
Slide 5: The litigation process against Actavis with an unexpected outcome in the district court
The litigation process against Actavis with an unexpected outcome in the district court Infringement by Actavis with their generic Validity and infringement of Zubsolv® patents versions of Suboxone® and Subutex® • First decision by the district court in • Orexo alleges that Actavis’s generic version
Slide 6: Top strategic priorities
Top strategic priorities Expand the commercial Maximize Zubsolv´s portfolio with revenue Expand the pipeline potential generating products Grow Zubsolv® sales Additional commercial Developing products for products in the US the oral tract and in Launch Zubsolv in new particular sublingual markets to
Slide 7: Commercial products and development pipeline
Commercial products and development pipeline We are now developing next generation drug delivery technologies Discussions ongoing Discussions ongoing 7
Slide 8: Our key market has continued growth trend, while waiting for new inflection point
Our key market has continued growth trend, while waiting for new inflection point New legislative changes expected to increase growth rate Quarterly NTRx levels continue to increase 2 700 000 Q4 YoY growth of 7,6% Q1 2017 YoY growth >9% 2 500 000 2 300 000 2 100 000 1 900 000 1 700 000 1 500 000 Q4
Slide 9: Tablets TRx Tablet Market Share
Slow down in Q4 primarily caused by changes in Maryland, WellCare and United Health Group Zubsolv® Market share (4 week average, %) Zubsolv Tablet Volume (rolling 4 weeks) Average weekly market share Average weekly sales 7,0% 400 000 Maryland 6,0% 350 000 TRx Tablet Market Share1 300 000 CVS 5,0% Ca
Slide 10: Two isolated events caused a drop in Zubsolv sales
Two isolated events caused a drop in Zubsolv® sales Growth continued positive when excluding these events • Approximately 1,250 NTRx1 in weekly volumes lost due to two isolated events – SelfRefind, a provider group in Kentucky left WellCare from December 1 – United Health Group (UHG) exited most hea
Slide 11: Managed Medicaid driving growth while Commercial remains the most important segment
Managed Medicaid driving growth while Commercial remains the most important segment Segment share of total national NTRx volume (percent) Comments % Managed Medicaid growth likely 60 positively influenced by the 50 Affordable Care Act 2012 Q4 2015 Q4 2016 40 Rebate agreements with Managed Medicaid a
Slide 12: Zubsolv starting to show positive share capture of the physicians increasing to 275 patients
Zubsolv® starting to show positive share capture of the physicians increasing to 275 patients Market access and sales force key to gain share Zubsolv share capture of C275 growth Comments 16% Orexo sales force covers 60% of C275 physician prescribing 14% volumes in Q4 12% 10% 78% of the 2,600 C275 p
Slide 13: Zubsolv well positioned to improve share in 2017 despite loss around year-end
Zubsolv® well positioned to improve share in 2017 despite loss around year-end Expanded treatment of opioid dependence will bring new growth opportunities • Fast growth in physicians certified to treat 275 patients • Strong indications of a continued political interest in expanding access to treatme
Slide 14: 2017 set up to be an eventful year!
2017 set up to be an eventful year! Development Supply Commercial Announcement of Complete Addition of commercial new OX-xx project, establishment of product to US organization following successful global supply chain Increased market share proof of principle in and confirmation on during th
Slide 15: Q&A
Q&A For more information please visit www.orexo.com. You can IR Contact: Lena Wange, IR & Communications Manager also follow Orexo at Twitter @orexoabpubl, LinkedIn and ir@orexo.com YouTube